| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6923983 | PADAGIS US | Transdermal delivery of hormones |
Feb, 2017
(7 years ago) | |
| US6299900 | PADAGIS US | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US6818226 | PADAGIS US | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US6978945 | PADAGIS US | Dispensing device |
Jul, 2022
(1 year, 8 months ago) | |
Evamist is owned by Padagis Us.
Evamist contains Estradiol.
Evamist has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Evamist are:
- US6923983
- US6299900
- US6818226
- US6978945
Evamist was authorised for market use on 27 July, 2007.
Evamist is available in spray;transdermal dosage forms.
Evamist can be used as female hormone replacement therapy for postmenopausal women.
The generics of Evamist are possible to be released after 31 July, 2022.
Drugs and Companies using ESTRADIOL ingredient
Market Authorisation Date: 27 July, 2007
Treatment: Female hormone replacement therapy for postmenopausal women
Dosage: SPRAY;TRANSDERMAL
More Information on Dosage
EVAMIST family patents
